Discontinuation and non-adherence to endocrine therapy in breast cancer patients: is lack of communication the decisive factor?

  • P. Wuensch
  • A. Hahne
  • R. Haidinger
  • K. Meißler
  • B. Tenter
  • C. Stoll
  • B. Senf
  • J. Huebner
Original Article – Cancer Research

Abstract

Introduction

Non-adherence to anti-hormonal therapy is a major problem in gynecologic oncology. Reasons reported are side effects and lack of support. The aim of our study was an analysis of influence of experiences of patients with endocrine therapy and communication and information on this topic and their influence on adherence.

Methods

We developed a structured questionnaire which was tested in a pilot version and then programmed as online questionnaire and presented to patient members of self-help and breast cancer organizations.

Results

Patients only had received scarce information on endocrine therapy. Only 12.8 % stated that their questions were answered in detail, 43.2 % got no answers or only non-detailed answers. 76 % had side effects limiting functions of daily life. 60 % of physicians did not react on these side effects. There is a significant correlation between number and intensity of side effects and non-adherence or disruption of therapy (p = 0.029 and p < 0.01, respectively). Women who reported having received detailed answers to their questions also reported better adherence (p = 0.014).

Conclusion

In order to improve adherence, detailed information on side effects and answers in case of symptoms are most important. Physicians should not rely on presenting written information but should mainly engage in direct communication.

Keywords

Endocrine therapy Non-adherence Communication Side effects 

Supplementary material

432_2014_1779_MOESM1_ESM.docx (22 kb)
Supplementary material 1 (DOCX 22 kb)

References

  1. Bell RJ, Fradkin P, Schwarz M, Davis SR (2013) Understanding discontinuation of oral adjuvant endocrine therapy by women with hormone receptor-positive invasive breast cancer nearly 4 years from diagnosis. Menopause 20(1):15–21PubMedCrossRefGoogle Scholar
  2. Chlebowski RT, Geller ML (2006) Adherence to endocrine therapy for breast cancer. Oncology 71(1–2):1–9PubMedGoogle Scholar
  3. Cluze C, Rey D, Huiart L, BenDiane MK, Bouhnik AD, Berenger C, Carrieri MP, Giorgi R (2012) Adjuvant endocrine therapy with tamoxifen in young women with breast cancer: determinants of interruptions vary over time. Ann Oncol 23:882–890PubMedCrossRefGoogle Scholar
  4. Güth U, Huang DJ, Schötzau A, Zanetti-Dällenbach R, Holzgreve W, Bitzer J, Wight E (2008) Target and reality of adjuvant endocrine therapy in postmenopausal patients with invasive breast cancer. Br J Cancer 99(3):428–433PubMedCentralPubMedCrossRefGoogle Scholar
  5. Güth U, Myrick ME, Kilic N, Eppenberger-Castori S, Schmid SM (2012) Compliance and persistence of endocrine adjuvant breast cancer therapy. Breast Cancer Res Treat 131(2):491–499PubMedCrossRefGoogle Scholar
  6. Hadjy P, Blettner M, Harbeck N, Jackisch C, Lück HJ, Windemuth-Kieselbach C, Zaun S, Kreienberg R (2013) The patient’s anastrozole compliance to therapy (PACT) program: a randomized, in-practice study in the impact of a standardized information program on persistence and compliance to adjuvant endocrine therapy in postmenopausal women with early breast cancer. Ann Oncol 24:505–512Google Scholar
  7. Hershman DL, Kushi LH, Shao T, Buono D, Kershenbaum A, Tsai WY, Fehrenbacher L, Gomez SL, Miles S, Neugut AI (2010) Early discontinuation and nonadherence to adjuvant hormonal therapy in a cohort of 8,769 early-stage breast cancer patients. J Clin Oncol 28(27):4120–4128PubMedCentralPubMedCrossRefGoogle Scholar
  8. Howell A, Cuzick J, Baum M, Buzdar A, Dowsett M, Forbes JF, Hoctin-Boes G, Houghton J, Locker GY, Tobias JS (2005) ATAC Trialists’ group: results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years’ adjuvanttreatment for breast cancer. Lancet 365:60–62PubMedCrossRefGoogle Scholar
  9. Huiart L, Dell’Aniello S, Suissa S (2011) Use of tamoxifen and aromatase inhibitors in a large population-based cohort of women with breast cancer. Br J Cancer 104(10):1558–1563PubMedCentralPubMedCrossRefGoogle Scholar
  10. Land SR, Cronin WM, Wickerham DL, Costantino JP, Christian NJ, Klein WM, Ganz PA (2011) Cigarette smoking, obesity, physical activity, and alcohol use as predictors of chemoprevention adherence in the National Surgical Adjuvant Breast and Bowel Project P-1 Breast Cancer Prevention Trial. Cancer Prev Res (Phila) 4(9):1393–1400CrossRefGoogle Scholar
  11. Lash TL, Fox MP, Westrup JL, Fink AK, Silliman RA (2006) Adherence to tamoxifen over the five-year course. Breast Cancer Res Treat 99:215–220PubMedCrossRefGoogle Scholar
  12. Liu Y, Malin JL, Diamant AL, Thind A, Maly RC (2013) Adherence to adjuvant hormone therapy in low-income women with breast cancer: the role of provider-patient communication. Breast Cancer Res Treat 137:829–836PubMedCentralPubMedCrossRefGoogle Scholar
  13. Murphy CC, Bartholomew LK, Carpentier MY, Bluethmann SM, Vernon SW (2012) Adherence to adjuvant hormonal therapy among breast cancer survivors in clinical practice: a systematic review. Breast Cancer Res Treat 134(2):459–478PubMedCentralPubMedCrossRefGoogle Scholar
  14. Nekhlyudov L, Li L, Ross-Degnan D, Wagner AK (2011) Five-year patterns of adjuvant hormonal therapy use, persistence, and adherence among insured women with early-stage breast cancer. Breast Cancer Res Treat 130(2):681–689PubMedCrossRefGoogle Scholar
  15. Partridge AH, Wang PS, Winer EP, Avorn J (2003) Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer. J Clin Oncol 21:602–606PubMedCrossRefGoogle Scholar
  16. Thurlimann B, Coates AS, Mouridsen H, Mauriac L, Forbes JF, Paridaens R, Castiglione-Gertsch M, Gelber RD, Rabaglio M, Smith I, Wardley A, Price KN, Goldhirsch A (2005) Breast international group (BIG) 1–98 collaborative group: a comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 353:2747–2757PubMedCrossRefGoogle Scholar
  17. van de Water W, Bastiaannet E, Hille ET, Meershoek-Klein Kranenbarg EM, Putter H, Seynaeve CM, Paridaens R, de Craen AJ, Westendorp RG, Liefers GJ, van de Velde CJ (2012) Age-specific nonpersistence of endocrine therapy in postmenopausal patients diagnosed with hormone receptor-positive breast cancer: a TEAM study analysis. Oncologist 17(1):55–63PubMedCentralPubMedCrossRefGoogle Scholar
  18. van Herk-Sukel MP, van de Poll-Franse LV, Voogd AC, Nieuwenhuijzen GA, Coebergh JW, Herings RM (2010) Half of breast cancer patients discontinue tamoxifen and any endocrine treatment before the end of the recommended treatment period of 5 years: a population-based analysis. Breast Cancer Res Treat 122(3):843–851PubMedCrossRefGoogle Scholar
  19. Wigertz A, Ahlgren J, Holmqvist M, Fornander T, Adolfsson J, Lindman H, Bergkvist L, Lambe M (2012) Adherence and discontinuation of adjuvant hormonal therapy in breast cancer patients: a population-based study. Breast Cancer Res Treat 133(1):367–373PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2014

Authors and Affiliations

  • P. Wuensch
    • 1
  • A. Hahne
    • 2
  • R. Haidinger
    • 3
  • K. Meißler
    • 4
  • B. Tenter
    • 5
  • C. Stoll
    • 6
  • B. Senf
    • 7
  • J. Huebner
    • 1
  1. 1.Working Group Integrative Oncology, Dr. Senckenberg Chronomedical InstituteJ. W. Goethe UniversityFrankfurtGermany
  2. 2.BRCA-NetworkHaus der Krebsselbsthilfe BonnBonnGermany
  3. 3.Brustkrebs Deutschland e.V.MunichGermany
  4. 4.Frauenselbsthilfe nach KrebsHaus der Krebsselbsthilfe BonnBonnGermany
  5. 5.KombraHamburgGermany
  6. 6.Clinic Herzoghoehe BayreuthBayreuthGermany
  7. 7.Division for PsychooncologyJ. W. Goethe UniversityFrankfurtGermany

Personalised recommendations